THE TREATMENT- ASSOCIATED SIDE EFFECTS IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA
(Abstract release date: 05/19/16)
EHA Library. Găman M. 06/09/16; 135013; PB2113
Dr. Mihnea-Alexandru Găman
Contributions
Contributions
Abstract
Abstract: PB2113
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is a disease characterized by the presence of antiplatelet antibodies which accelerate platelet destruction and prevent the release of platelets from megakaryocytes, resulting in various types of bleeding. The primary objective of treatment is to prevent bleeding by increasing the platelet count by reducing destruction of antibody-coated platelets (e.g. corticosteroids, immunoglobulins, splenectomy) or by stimulating platelet production (thrombopoietin receptor agonists, TPO-RAs) with the fewest possible side effects associated with treatment.
Aims
To evaluate the side effects associated with treatment and the quality of life in patients with ITP treated with corticosteroids versus TPO-RAs.
Methods
We studied 34 patients with ITP hospitalized in the Clinic of Hematology of Craiova (informed consent obtained) in between 2013 and 2015. Twenty-five patients received corticosteroids (prednisone or high dose dexamethasone) as first line therapy and nine patients with refractory or relapsed ITP were treated with eltrombopag (50 mg once daily as initial dose, followed by 25 mg once daily after platelet count ≥ 150.000/μL). We evaluated the side effects associated with treatment in both groups. We mention that patients treated with eltrombopag did have not hepatitis B/C or HIV infection, severe cardiovascular diseases or risk factors for thrombosis.
Results
Nineteen patients (76%) treated with corticosteroids presented one or more complications: infections (fungal, bacterial, viral) - 10 cases, arterial hypertension - 4 cases, duodenal ulcer hemorrhage - 1 case, dyspepsia - 2 cases, decompensation of diabetes mellitus - 2 cases, hyperglycemia - 3 cases, cataract - 1 case, insomnia - 2 cases, anxiety - 1 case, peripheral edema - 4 cases. Five patients (55%) treated with eltrombopag presented: headache - 1 case, transient increase of alanin aminotransferase - 3 cases, indirect hyperbilirubinemia - 1 case.
Conclusion
The treatment with eltrombopag was responsible for less side effects (and also less severe) in comparison with the treatment with corticosteroids, and contributed to the improvement of the quality of life in patients with ITP.
Session topic: E-poster
Keyword(s): Corticosteroids, Idiopathic thombocytopenic purpura (ITP), Side effects, Thrombopoietin (TPO)
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is a disease characterized by the presence of antiplatelet antibodies which accelerate platelet destruction and prevent the release of platelets from megakaryocytes, resulting in various types of bleeding. The primary objective of treatment is to prevent bleeding by increasing the platelet count by reducing destruction of antibody-coated platelets (e.g. corticosteroids, immunoglobulins, splenectomy) or by stimulating platelet production (thrombopoietin receptor agonists, TPO-RAs) with the fewest possible side effects associated with treatment.
Aims
To evaluate the side effects associated with treatment and the quality of life in patients with ITP treated with corticosteroids versus TPO-RAs.
Methods
We studied 34 patients with ITP hospitalized in the Clinic of Hematology of Craiova (informed consent obtained) in between 2013 and 2015. Twenty-five patients received corticosteroids (prednisone or high dose dexamethasone) as first line therapy and nine patients with refractory or relapsed ITP were treated with eltrombopag (50 mg once daily as initial dose, followed by 25 mg once daily after platelet count ≥ 150.000/μL). We evaluated the side effects associated with treatment in both groups. We mention that patients treated with eltrombopag did have not hepatitis B/C or HIV infection, severe cardiovascular diseases or risk factors for thrombosis.
Results
Nineteen patients (76%) treated with corticosteroids presented one or more complications: infections (fungal, bacterial, viral) - 10 cases, arterial hypertension - 4 cases, duodenal ulcer hemorrhage - 1 case, dyspepsia - 2 cases, decompensation of diabetes mellitus - 2 cases, hyperglycemia - 3 cases, cataract - 1 case, insomnia - 2 cases, anxiety - 1 case, peripheral edema - 4 cases. Five patients (55%) treated with eltrombopag presented: headache - 1 case, transient increase of alanin aminotransferase - 3 cases, indirect hyperbilirubinemia - 1 case.
Conclusion
The treatment with eltrombopag was responsible for less side effects (and also less severe) in comparison with the treatment with corticosteroids, and contributed to the improvement of the quality of life in patients with ITP.
Session topic: E-poster
Keyword(s): Corticosteroids, Idiopathic thombocytopenic purpura (ITP), Side effects, Thrombopoietin (TPO)
Abstract: PB2113
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is a disease characterized by the presence of antiplatelet antibodies which accelerate platelet destruction and prevent the release of platelets from megakaryocytes, resulting in various types of bleeding. The primary objective of treatment is to prevent bleeding by increasing the platelet count by reducing destruction of antibody-coated platelets (e.g. corticosteroids, immunoglobulins, splenectomy) or by stimulating platelet production (thrombopoietin receptor agonists, TPO-RAs) with the fewest possible side effects associated with treatment.
Aims
To evaluate the side effects associated with treatment and the quality of life in patients with ITP treated with corticosteroids versus TPO-RAs.
Methods
We studied 34 patients with ITP hospitalized in the Clinic of Hematology of Craiova (informed consent obtained) in between 2013 and 2015. Twenty-five patients received corticosteroids (prednisone or high dose dexamethasone) as first line therapy and nine patients with refractory or relapsed ITP were treated with eltrombopag (50 mg once daily as initial dose, followed by 25 mg once daily after platelet count ≥ 150.000/μL). We evaluated the side effects associated with treatment in both groups. We mention that patients treated with eltrombopag did have not hepatitis B/C or HIV infection, severe cardiovascular diseases or risk factors for thrombosis.
Results
Nineteen patients (76%) treated with corticosteroids presented one or more complications: infections (fungal, bacterial, viral) - 10 cases, arterial hypertension - 4 cases, duodenal ulcer hemorrhage - 1 case, dyspepsia - 2 cases, decompensation of diabetes mellitus - 2 cases, hyperglycemia - 3 cases, cataract - 1 case, insomnia - 2 cases, anxiety - 1 case, peripheral edema - 4 cases. Five patients (55%) treated with eltrombopag presented: headache - 1 case, transient increase of alanin aminotransferase - 3 cases, indirect hyperbilirubinemia - 1 case.
Conclusion
The treatment with eltrombopag was responsible for less side effects (and also less severe) in comparison with the treatment with corticosteroids, and contributed to the improvement of the quality of life in patients with ITP.
Session topic: E-poster
Keyword(s): Corticosteroids, Idiopathic thombocytopenic purpura (ITP), Side effects, Thrombopoietin (TPO)
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is a disease characterized by the presence of antiplatelet antibodies which accelerate platelet destruction and prevent the release of platelets from megakaryocytes, resulting in various types of bleeding. The primary objective of treatment is to prevent bleeding by increasing the platelet count by reducing destruction of antibody-coated platelets (e.g. corticosteroids, immunoglobulins, splenectomy) or by stimulating platelet production (thrombopoietin receptor agonists, TPO-RAs) with the fewest possible side effects associated with treatment.
Aims
To evaluate the side effects associated with treatment and the quality of life in patients with ITP treated with corticosteroids versus TPO-RAs.
Methods
We studied 34 patients with ITP hospitalized in the Clinic of Hematology of Craiova (informed consent obtained) in between 2013 and 2015. Twenty-five patients received corticosteroids (prednisone or high dose dexamethasone) as first line therapy and nine patients with refractory or relapsed ITP were treated with eltrombopag (50 mg once daily as initial dose, followed by 25 mg once daily after platelet count ≥ 150.000/μL). We evaluated the side effects associated with treatment in both groups. We mention that patients treated with eltrombopag did have not hepatitis B/C or HIV infection, severe cardiovascular diseases or risk factors for thrombosis.
Results
Nineteen patients (76%) treated with corticosteroids presented one or more complications: infections (fungal, bacterial, viral) - 10 cases, arterial hypertension - 4 cases, duodenal ulcer hemorrhage - 1 case, dyspepsia - 2 cases, decompensation of diabetes mellitus - 2 cases, hyperglycemia - 3 cases, cataract - 1 case, insomnia - 2 cases, anxiety - 1 case, peripheral edema - 4 cases. Five patients (55%) treated with eltrombopag presented: headache - 1 case, transient increase of alanin aminotransferase - 3 cases, indirect hyperbilirubinemia - 1 case.
Conclusion
The treatment with eltrombopag was responsible for less side effects (and also less severe) in comparison with the treatment with corticosteroids, and contributed to the improvement of the quality of life in patients with ITP.
Session topic: E-poster
Keyword(s): Corticosteroids, Idiopathic thombocytopenic purpura (ITP), Side effects, Thrombopoietin (TPO)
{{ help_message }}
{{filter}}